🎉 M&A multiples are live!
Check it out!

FibroGen Valuation Multiples

Discover revenue and EBITDA valuation multiples for FibroGen and similar public comparables like Pharming, Galapagos, and Vivoryon Therapeutics.

FibroGen Overview

About FibroGen

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.


Founded

1993

HQ

United States of America
Employees

225

Website

fibrogen.com

Financials

LTM Revenue $22.8M

LTM EBITDA -$64.9M

EV

$52.9M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

FibroGen Financials

FibroGen has a last 12-month revenue of $22.8M and a last 12-month EBITDA of -$64.9M.

In the most recent fiscal year, FibroGen achieved revenue of $29.6M and an EBITDA of -$142M.

FibroGen expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See FibroGen valuation multiples based on analyst estimates

FibroGen P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $148M $29.6M XXX XXX XXX
Gross Profit $120M $129M XXX XXX XXX
Gross Margin 82% 435% XXX XXX XXX
EBITDA -$261M -$142M XXX XXX XXX
EBITDA Margin -177% -481% XXX XXX XXX
Net Profit -$294M -$284M XXX XXX XXX
Net Margin -199% -960% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

FibroGen Stock Performance

As of April 15, 2025, FibroGen's stock price is $0.

FibroGen has current market cap of $30.3M, and EV of $52.9M.

See FibroGen trading valuation data

FibroGen Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$52.9M $30.3M XXX XXX XXX XXX $-0.51

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

FibroGen Valuation Multiples

As of April 15, 2025, FibroGen has market cap of $30.3M and EV of $52.9M.

FibroGen's trades at 2.3x LTM EV/Revenue multiple, and -0.8x LTM EBITDA.

Analysts estimate FibroGen's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for FibroGen and 10K+ public comps

FibroGen Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $52.9M XXX XXX XXX
EV/Revenue 1.8x XXX XXX XXX
EV/EBITDA -0.4x XXX XXX XXX
P/E -0.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get FibroGen Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

FibroGen Valuation Multiples

FibroGen's NTM/LTM revenue growth is -72%

FibroGen's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.6M for the same period.

Over next 12 months, FibroGen's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate FibroGen's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for FibroGen and other 10K+ public comps

FibroGen Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -80% XXX XXX XXX XXX
EBITDA Margin -481% XXX XXX XXX XXX
EBITDA Growth -46% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -553% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 323% XXX XXX XXX XXX
Opex to Revenue 490% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

FibroGen Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

FibroGen M&A and Investment Activity

FibroGen acquired  XXX companies to date.

Last acquisition by FibroGen was  XXXXXXXX, XXXXX XXXXX XXXXXX . FibroGen acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by FibroGen

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About FibroGen

When was FibroGen founded? FibroGen was founded in 1993.
Where is FibroGen headquartered? FibroGen is headquartered in United States of America.
How many employees does FibroGen have? As of today, FibroGen has 225 employees.
Who is the CEO of FibroGen? FibroGen's CEO is Mr. Thane Wettig.
Is FibroGen publicy listed? Yes, FibroGen is a public company listed on NAS.
What is the stock symbol of FibroGen? FibroGen trades under FGEN ticker.
When did FibroGen go public? FibroGen went public in 2014.
Who are competitors of FibroGen? Similar companies to FibroGen include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of FibroGen? FibroGen's current market cap is $30.3M
What is the current revenue of FibroGen? FibroGen's last 12-month revenue is $22.8M.
What is the current EBITDA of FibroGen? FibroGen's last 12-month EBITDA is -$64.9M.
What is the current EV/Revenue multiple of FibroGen? Current revenue multiple of FibroGen is 2.3x.
What is the current EV/EBITDA multiple of FibroGen? Current EBITDA multiple of FibroGen is -0.8x.
What is the current revenue growth of FibroGen? FibroGen revenue growth between 2023 and 2024 was -80%.
Is FibroGen profitable? Yes, FibroGen is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.